基于糖蛋白E的ELISA与水痘-带状疱疹全病毒ELISA在幼儿水痘疫苗免疫应答定量中的比较
本研究在12-23月龄幼儿III期试验(NCT02570126)中比较抗VZV糖蛋白E(anti-gE)ELISA与抗VZV全病毒ELISA测定的抗体浓度。397名儿童1138份样本中,anti-VZV阳性757份(≥25 mIU/mL),anti-gE阳性758份(≥97 mIU/mL),总体一致率99.03%(95%CI 98.28-99.52;McNemar P=1)。双阳性样本抗体几何平均浓度比值(anti-gE/anti-VZV)总体为3.78。
要点
- anti-gE ELISA与anti-VZV ELISA总体一致率99.03%(95%CI 98.28-99.52)
- 双阳性样本抗体几何平均浓度比值(anti-gE/anti-VZV)总体为3.78
- anti-gE ELISA可作为评估新型水痘疫苗抗体应答的有效替代方法
核心结论
- anti-gE ELISA是评估新型水痘疫苗与对照疫苗抗体应答的有效替代方法。
研究设计与样本
- 研究在12-23月龄接受两剂水痘疫苗的III期试验(NCT02570126)中,比较anti-gE ELISA与anti-VZV ELISA测定的抗体浓度。
- 共检测来自397名儿童的1138份样本(每次接种前和接种后42天),样本初检用anti-VZV ELISA,复检用anti-gE ELISA。
主要发现
- 1138份样本中,anti-VZV ELISA阳性(抗体浓度≥25 mIU/mL)757份,anti-gE ELISA阳性(≥97 mIU/mL)758份。
- 双阴性样本375份,不一致样本仅11份。
- 总体一致率为99.03%(95%置信区间:98.28-99.52;McNemar P值=1)。
- 752份双阳性样本的抗体几何平均浓度比值(anti-gE/anti-VZV)总体为3.78,第一剂后为4.75,第二剂后为3.01。
关键数值与推荐
- anti-VZV ELISA阳性阈值:抗体浓度≥25 mIU/mL。
- anti-gE ELISA阳性阈值:抗体浓度≥97 mIU/mL。
- 总体一致率99.03%(95%CI 98.28-99.52;McNemar P=1)。
- 双阳性样本抗体几何平均浓度比值(anti-gE/anti-VZV):总体3.78,第一剂后4.75,第二剂后3.01。
临床怎么用
- anti-gE ELISA可用于评估新型水痘疫苗与已有疫苗对照的抗体应答试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody response against varicella-zoster virus (VZV) is frequently assessed by whole-virus- (anti-VZV) or glycoprotein-based ELISAs. This study compared antibody concentrations measured by an assay quantifying anti-VZV glycoprotein E (anti-gE) and anti-VZV ELISA in 12-23-month-olds, receiving two varicella vaccine doses in a phase III trial (NCT02570126). Samples (pre- and 42 days post-each vaccination) initially tested with anti-VZV ELISA were re-tested with anti-gE ELISA. Of 1138 samples from 397 children, 757 were positive by anti-VZV (antibody concentration ≥25 mIU/mL) and 758 by anti-gE ELISA (≥97 mIU/mL). There were 375 double-negative and only 11 discrepant samples. The overall agreement was 99.03% (95% confidence interval: 98.28-99.52; McNemar p-value = 1). The ratio between antibody geometric mean concentrations (anti-gE/anti-VZV) for the 752 double-positive samples was 3.78 overall, 4.75 post-first, and 3.01 post-second vaccination. The anti-gE ELISA is a valid alternative for trials assessing antibody response to new varicella vaccines versus established ones, used as control.
引用
- Feyssaguet M, Berthold V, Helle L, et al. Comparison of a glycoprotein E-based ELISA with a varicella-zoster whole-virus ELISA for the quantification of varicella vaccine immune responses in young children. Vaccine. 2020. PMID: 32184033. doi:10.1016/j.vaccine.2020.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。